Neurology Medical News about recurrent malignant glioma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Neuro-Oncology, 10/06/09

Quinn JA et al. – This phase I clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG) was designed to determine the maximum tolerated dose (MTD) and toxicity of three different 5–day dosing regimens of temozolomide (TMZ) in combination with O6–benzylguanine (O6–BG). This study provides the foundation for a phase II trial of O6–BG in combination with a 5–day dosing schedule of TMZ in TMZ–resistant MG.

<< Previous
Isolated head tremor: Part of the clinical spectrum of essential...

Next >>
Radiation-induced meningiomas: A shadow in the success story of...

Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults
BMC Cancer, 10/22/09 Relevance Score: 80%

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Neuro-Oncology, 10/06/09 Relevance Score: 80%

Treatment of recurrent high-grade gliomas
Current Opinion in Neurology, 11/12/09 Relevance Score: 68%

MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells
Journal of Neuro-Oncology, 11/04/09 Relevance Score: 68%

Methyl-L-11C-Methionine PET as a Diagnostic Marker for Malignant Progression in Patients with Glioma
The Journal of Nuclear Medicine, 11/18/09 Relevance Score: 67%